Cullinan Therapeutics, Inc. has announced significant preclinical data for its investigational therapy CLN-978, which targets autoimmune diseases. The data, showcasing rapid and profound B cell depletion in both in vitro and in vivo models, will be presented at the American College of Rheumatology (ACR) Convergence 2025. This event is taking place in Chicago, Illinois, from October 24 to 29, with Cullinan’s poster presentation scheduled for October 28 from 10:30 a.m. to 12:30 p.m. CT.
The findings demonstrate the potential of CLN-978, a novel CD19xCD3 bispecific T cell engager, to effectively reduce B cell populations implicated in various autoimmune disorders. These results not only highlight the therapeutic promise of CLN-978 but also position Cullinan as a key player in the development of innovative treatments for these challenging conditions.
Presentation and Engagement at ACR 2025
Cullinan will showcase its research during a dedicated poster session at the ACR event, which is one of the premier gatherings for professionals in the rheumatology field. The company will also have a presence in the Exhibit Hall at Booth #1074, offering attendees the opportunity to engage with their research team and learn more about their ongoing projects.
The ACR Convergence is a significant platform for presenting new scientific findings and fostering collaborations among researchers and clinicians. By participating in this event, Cullinan aims to not only share its recent advancements but also to gather insights from peers in the field of rheumatology.
Focus on Innovative Therapies
As a clinical-stage biopharmaceutical company, Cullinan Therapeutics is dedicated to developing potential first- or best-in-class therapies for patients suffering from autoimmune diseases and cancer. The preclinical data for CLN-978 is a testament to their commitment to scientific innovation and patient care.
The rapid B cell depletion observed with CLN-978 could lead to improved treatment options for patients with conditions characterized by excessive or dysregulated B cell activity. This includes diseases such as rheumatoid arthritis and lupus, where B cells play a critical role in disease progression.
By advancing their research and sharing these findings at high-profile conferences like ACR, Cullinan Therapeutics continues to reinforce its position in the competitive biopharmaceutical landscape. The company’s innovative approach to targeting B cells represents a promising avenue for future therapies aimed at managing autoimmune diseases effectively.
